Abstract | IMPORTANCE: About 40 000 Americans and 2 million people worldwide are newly infected with HIV each year. The combination antiretroviral regimen, tenofovir disoproxil fumarate (TDF)/ emtricitabine, taken as a single pill once daily, has been shown to prevent HIV transmission but is used by fewer than 20% of people who could benefit in the United States. OBSERVATIONS: PubMed was searched on February 15, 2018, using the search terms pre-exposure, prophylaxis, HIV, and PrEP to identify English-language articles published between 2010 and 2018. Four placebo-controlled randomized clinical trials have demonstrated that preexposure prophylaxis (PrEP) with daily dosing of TDF/ emtricitabine significantly reduces HIV acquisition in men who have sex with men, high-risk heterosexuals, and injection drug users who share injection equipment. The efficacy of daily TDF/ emtricitabine exceeds 90% but is highly correlated with degree of adherence. TDF/ emtricitabine is safe and well-tolerated. Only 2% of people discontinue PrEP because of adverse effects. Sexually transmitted infections are common among those using PrEP. Resistance to TDF/ emtricitabine when used for PrEP is rare (<0.1%) and usually occurs when PrEP is inadvertently prescribed to individuals with undiagnosed acute HIV infection who have false-negative findings on HIV antibody/ antigen testing due to HIV infection acquired within 7 to 10 days of testing. Effective methods are needed to identify individuals at high risk for acquiring HIV, ensure their access to PrEP, and maximize medication adherence. CONCLUSIONS AND RELEVANCE:
|
Authors | James Riddell 4th, K Rivet Amico, Kenneth H Mayer |
Journal | JAMA
(JAMA)
Vol. 319
Issue 12
Pg. 1261-1268
(Mar 27 2018)
ISSN: 1538-3598 [Electronic] United States |
PMID | 29584848
(Publication Type: Journal Article, Review)
|
Chemical References |
- Anti-HIV Agents
- Drug Combinations
- Tenofovir
- Emtricitabine
|
Topics |
- Anti-HIV Agents
(adverse effects, therapeutic use)
- Disease Transmission, Infectious
(prevention & control)
- Drug Combinations
- Emtricitabine
(adverse effects, therapeutic use)
- HIV Infections
(prevention & control, transmission)
- Humans
- Pre-Exposure Prophylaxis
- Risk Factors
- Tenofovir
(adverse effects, therapeutic use)
|